Patent Profile: Immunomedics Announces Issuance of Patent for anti-CD20 Antibody
Patent Docs: By Donald Zuhn — Last week, Immunomedics, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,435,803, which is directed to humanized and chimeric anti-CD20 antibodies and CD20 antibody fusion proteins. Such antibodies are useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases. The ‘803 patent is Immunomedics’ 131st U.S. patent, which is also named as an assignee on 111 U.S. patent application publications. CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of all mature B-cells, and which plays a role in the development and…